Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

NCT00290433 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: Cyclophosphamide
DRUG: Mesna
DRUG: Vincristine
DRUG: Methotrexate
DRUG: Ara-C
DRUG: Dexamethasone
DRUG: G-CSF
DRUG: Doxil

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]